Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MRTX 1133

Next Previous
Drug Profile

MRTX 1133

Alternative Names: MRTX-1133

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma; Mirati Therapeutics
  • Developer Mirati Therapeutics; University of Alabama at Birmingham
  • Class Antineoplastics; Azabicyclo compounds; Cyclic hydrocarbons; Ethers; Fluorinated hydrocarbons; Naphthols; Pyridines; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Multiple myeloma; Pancreatic cancer
  • No development reported Cancer

Most Recent Events

  • 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 25 Apr 2025 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 03 Apr 2025 Mirati Therapeutics terminates a phase I/II trial in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA (PO) due to formulation challenges (NCT05737706)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top